You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Claims for Patent: 12,414,942

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,414,942

Title:	Compositions, methods, and systems for treating presbyopia
Abstract:	The present disclosure provides methods comprising administration protocols of an ophthalmological composition, such as comprising aceclidine.
Inventor(s):	Gerald Horn
Assignee:	Lenz Therapeutics Operations Inc
Application Number:	US18/939,325
Patent Claims:	1. A method of treating presbyopia in an individual, the method comprising administering a first drop of an ophthalmological composition to an eye of the individual and subsequently administering a second drop of the ophthalmological composition to the eye of the individual, the ophthalmological composition comprising aceclidine or a salt thereof, the second drop being administered to the eye of the individual about 2 minutes after the first drop is administered to the eye, wherein the ophthalmological composition comprises aceclidine in a free base concentration of about 1.44 wt. %. 2. A method of treating presbyopia in an individual, the method comprising administering a first drop of an ophthalmological composition to an eye of the individual and subsequently administering a second drop of the ophthalmological composition to the eye of the individual, the ophthalmological composition comprising aceclidine or a salt thereof, the second drop being administered to the eye of the individual about 2 minutes after the first drop is administered to the eye, wherein following administration of the ophthalmological composition to the eye, the individual has 3-lines or more improvement in the eye within 0.5 hours of administering the second drop to the eye, and the individual has 3-lines or more improvement for at least 8 hours in the eye. 3. A method for treating presbyopia, the method comprising instilling one drop of an ophthalmological composition comprising aceclidine or a salt thereof in each eye followed by a second drop in each eye about two (2) minutes later for an effect of at least 10 hours, wherein the ophthalmological composition is preservative-free. 4. A method for treating presbyopia, the method comprising instilling one drop of an ophthalmological composition comprising aceclidine or a salt thereof in each eye followed by a second drop in each eye about two (2) minutes later for an effect of at least 10 hours, wherein no more than a first drop and a second drop of the ophthalmological composition is administered to the eye in a day. 5. The method of claim 1, wherein following administration of the ophthalmological composition to the eye, the individual has 3-lines or more improvement in the eye within 0.5 hours of administering the second drop to the eye, and the individual has 3-lines or more improvement for at least 8 hours in the eye. 6. The method of claim 1, wherein the ophthalmological composition is preservative-free. 7. The method of claim 1, wherein no more than a first drop and a second drop of the ophthalmological composition is administered to the eye in a day. 8. The method of claim 2, wherein the ophthalmological composition comprises aceclidine in a free base concentration of about 1.44 wt. %. 9. The method of claim 2, wherein the ophthalmological composition is preservative-free. 10. The method of claim 2, wherein no more than a first drop and a second drop of the ophthalmological composition is administered to the eye in a day. 11. The method of claim 3, wherein the ophthalmological composition comprises aceclidine in a free base concentration of about 1.44 wt. %. 12. The method of claim 3, wherein following administration of the ophthalmological composition to the eye, the individual has 3-lines or more improvement in the eye within 0.5 hours of administering the second drop to the eye, and the individual has 3-lines or more improvement for at least 8 hours in the eye. 13. The method of claim 3, wherein no more than a first drop and a second drop of the ophthalmological composition is administered to the eye in a day. 14. The method of claim 4, wherein the ophthalmological composition comprises aceclidine in a free base concentration of about 1.44 wt. %. 15. The method of claim 4, wherein following administration of the ophthalmological composition to the eye, the individual has 3-lines or more improvement in the eye within 0.5 hours of administering the second drop to the eye, and the individual has 3-lines or more improvement for at least 8 hours in the eye. 16. The method of claim 4, wherein the ophthalmological composition is preservative-free.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.